Search Browse Earnings

BioXcel Therapeutics, Inc. — SlamSEC

BioXcel Therapeutics, Inc.

Nasdaq:BTAI

Pharmaceutical Preparations·NEW HAVEN, CT

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$1.4M

+268.0% YoY

FY 2024

Adj. EBITDA

-$171.6M

-12434.3% margin

FY 2024

Net Income

-$179.1M

-12974.9% margin

FY 2024

EPS (Diluted)

-$98.33

FY 2024

Stock Price

$1.55

-1.3%

2026-03-12

52W Range

$1.17 – $8.08

P/E Ratio

-0.0x

Market Cap

$33.9M

Cash

$65.2M

FY 2024

Total Debt

$100.6M

FY 2024

Net Debt

$35.4M

FY 2024

Enterprise Value

$69.3M

Debt / EBITDA

-0.2x

FY 2024

EV / EBITDA

-0.4x

Employees

—